OncLive TV

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Susan Bal, MD, discusses questions remaining regarding sequencing of treatments in later lines for patients with relapsed/refractory multiple myeloma.

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Sarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Ann M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses toxicities associated with various treatment options for patients with renal cell carcinoma.

Sarah E. S. Leary, MD, MS, discusses findings from the phase 2 FIREFLY-1 trial in pediatric patients with low-grade glioma.

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Pedro Barata, MD, MSc, discusses the relationship between the gut microbiome and treatment with immunotherapy in patients with renal cell carcinoma.

Robert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.

Sophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Jeffrey V. Matous, MD, discusses future directions of CAR T-cell therapy in multiple myeloma, highlighting the potential promise of novel targets beyond BCMA.

Kedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Nicole O Williams, MD, discusses unmet needs for patients with HER2-positive breast cancer and potential future research directions in the space.

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.

Sherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.

Lorenzo Falchi, MD, iscusses the use of glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.

Sarah Goldberg, MD, MPH, discusses the design and key objectives of an ongoing phase 1a/b study of VIC-1911 as a monotherapy and in combination with sotorasib in KRAS G12C–mutant non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the development of the seizure-related homolog protein 6–targeting antibody-drug conjugate ABBV-011 and outcomes with this agent in patients with small cell lung cancer.